Looking to build up its pipeline of future products, Eli Lilly (NYSE:LLY) aims to announce a $1B-5B deal for each quarter of 2020.
The acquisitions will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters.
The spree has already started. Last week, Eli Lilly announced a deal to buy dermatology products maker Dermira for $1.1B.
MCOA inks deal for CBD beverage products
Marijuana Company of America’s (OTCQB:MCOA) wholly owned subsidiary, hempSMART Inc., has signed a definitive sales agreement to purchase ultra-clean label CBD beverage products from MCTC Holdings (OTCPK:MCTC).
During the initial stage, MCOA will offer a line of powdered drink mixes containing hemp extracts with over 35 milligrams of CBD derived from all-natural extraction processes.
Future offerings will include other powdered and pre-mixed beverages.
Allergan launches new eye cream
Allergan (NYSE:AGN) has launched SkinMedica Instant Bright Eye Cream, an eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes.
SkinMedica is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.
Instant Bright products will be available for purchase online beginning April 2020.
MCig receives purchase order for CBD-based products
MCig (OTCPK:MCIG) subsidiary, BareRoots Rx Inc., the consumer products division, has entered into an agreement to distribute 10,000 monthly boxes of the CBD-based products to select tribal communities.
The company anticipates revenue of ~$1.1M in its first year of operation under the agreement and has also entered into a white labeling agreement with the cannabis company to supply ~$200,000 of CBD derivative products.
Tetra Bio to launch Terpacan products mid-year
Tetra Bio-Pharma (OTCQB:TBPMF) announces that Health Canada has issued two Drug Identification Numbers for its first OTC topical Terpacan products, one for hemorrhoids and the other for back & muscle pain.
Commercial launch in Canada will commence mid-year followed by launches in the U.S. and Europe (after regulatory approvals).
